| Overview |
| bs-6855R-Cy5 |
| NALP4 Polyclonal Antibody, Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| This antibody will detect multiple forms of NALP4, including the A, C and E Mouse variants. |
| Human, Mouse, Rat |
| Pig, Horse |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NALP4 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 147945 |
| Q96MN2 |
| Cytoplasm, Secreted, Extracellular matrix |
| NACHT, LRR and PYD domains-containing protein 4; Cancer/testis antigen 58; CT58; PAAD and NACHT-containing protein 2; PAN2; PYRIN and NACHT-containing protein 2; PYRIN-containing APAF1-like protein 4; PYPAF4; Ribonuclease inhibitor 2; NLRP4; NALP4; RNH2 |
| May be involved in inflammation and recognition of cytosolic pathogen-associated molecular patterns (PAMPs) not intercepted by membrane-bound receptors. Acts as a negative regulator of the type I interferon signaling pathway by serving as an adapter to promote DTX4-mediated ubiquitination of activated TBK1, and its subsequent degradation. Suppresses NF-kappaB induction by the cytokines TNFA and IL1B, suggesting that it operates at a point of convergence in these two cytokine signaling pathways. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz